JP2019528302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528302A5 JP2019528302A5 JP2019511500A JP2019511500A JP2019528302A5 JP 2019528302 A5 JP2019528302 A5 JP 2019528302A5 JP 2019511500 A JP2019511500 A JP 2019511500A JP 2019511500 A JP2019511500 A JP 2019511500A JP 2019528302 A5 JP2019528302 A5 JP 2019528302A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- amino
- acceptable salt
- methylureido
- dimethoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 17
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 10
- -1 6- (3- (2,6-dichloro-3,5-dimethoxyphenyl) -1-methylureido) pyrimidin-4-yl Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 claims 6
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims 3
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 3
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 229950001573 abemaciclib Drugs 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 229960004390 palbociclib Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- 229950003687 ribociclib Drugs 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims 1
- BBUVDDPUURMFOX-SAABIXHNSA-N AMG-925 Chemical compound C1C[C@@H](C)CC[C@@H]1N1C2=NC(NC=3N=C4CCN(CC4=CC=3)C(=O)CO)=NC=C2C2=CC=NC=C21 BBUVDDPUURMFOX-SAABIXHNSA-N 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378455P | 2016-08-23 | 2016-08-23 | |
| US62/378,455 | 2016-08-23 | ||
| PCT/US2017/048183 WO2018039324A1 (en) | 2016-08-23 | 2017-08-23 | Combination therapies for the treatment of hepatocellular carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528302A JP2019528302A (ja) | 2019-10-10 |
| JP2019528302A5 true JP2019528302A5 (OSRAM) | 2020-09-24 |
| JP7190425B2 JP7190425B2 (ja) | 2022-12-15 |
Family
ID=59772765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511500A Active JP7190425B2 (ja) | 2016-08-23 | 2017-08-23 | 肝細胞癌の治療のための併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190175598A1 (OSRAM) |
| EP (1) | EP3503923B1 (OSRAM) |
| JP (1) | JP7190425B2 (OSRAM) |
| KR (1) | KR102466192B1 (OSRAM) |
| CN (1) | CN109803684B (OSRAM) |
| AU (1) | AU2017315357B2 (OSRAM) |
| BR (1) | BR112019003722A2 (OSRAM) |
| CA (1) | CA3034875C (OSRAM) |
| ES (1) | ES2966469T3 (OSRAM) |
| IL (1) | IL264950B2 (OSRAM) |
| MX (1) | MX2019002115A (OSRAM) |
| RU (1) | RU2769251C2 (OSRAM) |
| SG (1) | SG11201901472TA (OSRAM) |
| WO (1) | WO2018039324A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| EP3793609B1 (en) | 2018-05-14 | 2023-12-13 | Pfizer Inc. | Oral solution formulation |
| TW202128174A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| JP2023533903A (ja) * | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法 |
| JP2025520303A (ja) | 2022-05-30 | 2025-07-03 | 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 | 癌治療用の医薬組み合わせ物および医薬組成物 |
| TW202523318A (zh) * | 2023-11-30 | 2025-06-16 | 大陸商石藥集團中奇製藥技術（石家莊）有限公司 | 聯合治療腫瘤的藥物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
| IL150643A0 (en) | 2000-01-18 | 2003-02-12 | Aventis Pharma Inc | Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 [4r-(3s-hydroxy-1-methyl) piperidinyl]-4h-1-benzopyran-4-one |
| JP2003520797A (ja) | 2000-01-18 | 2003-07-08 | アベンテイス・フアーマシユーチカルズ・インコーポレーテツド | （−）−シス−２−（２−クロロフェニル）−５，７−ジヒドロキシ−８［４Ｒ−（３Ｓ−ヒドロキシ−１−メチル）ピペリジニル］−４Ｈ−１−ベンゾピラン−４−オンの偽多形体（ｐｓｅｕｄｏｐｏｌｙｍｏｒｐｈ） |
| WO2002022133A1 (en) | 2000-09-12 | 2002-03-21 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| GEP20063909B (en) | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
| BRPI0412259B1 (pt) | 2003-07-22 | 2019-08-20 | Astex Therapeutics Limited | Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| CA2594477C (en) | 2005-01-21 | 2016-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| KR101345002B1 (ko) | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| US20080161355A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| WO2008007113A2 (en) | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| WO2008001101A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008007122A2 (en) | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's |
| EP2046327A1 (en) | 2006-07-21 | 2009-04-15 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| BRPI0913031A2 (pt) * | 2008-05-23 | 2019-11-26 | Novartis Ag | derivados de quinolina e quinoxalinas como inibidores de proteína tirosina quinase, seus usos e processo de fabricação, bem como composições farmacêuticas e combinação que os compreende |
| CN102186856B (zh) | 2008-08-22 | 2014-09-24 | 诺华股份有限公司 | 作为cdk抑制剂的吡咯并嘧啶化合物 |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| US20130035336A1 (en) * | 2010-04-13 | 2013-02-07 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer |
| SG10201508715YA (en) | 2010-10-25 | 2015-11-27 | G1 Therapeutics Inc | Cdk inhibitors |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| DK2688887T3 (en) * | 2011-03-23 | 2015-06-29 | Amgen Inc | DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3 |
| RU2014103250A (ru) * | 2011-07-01 | 2015-08-10 | Новартис Аг | Комбинированная терапия |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| WO2014097125A1 (en) * | 2012-12-20 | 2014-06-26 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| EP2968291B1 (en) | 2013-03-15 | 2025-04-16 | Pharmacosmos Holding A/S | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| ES2900829T3 (es) * | 2013-08-14 | 2022-03-18 | Novartis Ag | Terapia combinada para el tratamiento del cáncer |
| AR098048A1 (es) * | 2013-10-18 | 2016-04-27 | Eisai R&D Man Co Ltd | Inhibidores de fgfr4 |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
| WO2016126889A1 (en) | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| JP6431622B2 (ja) * | 2015-04-14 | 2018-11-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 結晶性ｆｇｆｒ４阻害剤化合物およびその使用 |
-
2017
- 2017-08-23 RU RU2019108259A patent/RU2769251C2/ru active
- 2017-08-23 CA CA3034875A patent/CA3034875C/en active Active
- 2017-08-23 WO PCT/US2017/048183 patent/WO2018039324A1/en not_active Ceased
- 2017-08-23 JP JP2019511500A patent/JP7190425B2/ja active Active
- 2017-08-23 ES ES17761701T patent/ES2966469T3/es active Active
- 2017-08-23 KR KR1020197008327A patent/KR102466192B1/ko active Active
- 2017-08-23 US US16/324,643 patent/US20190175598A1/en not_active Abandoned
- 2017-08-23 EP EP17761701.6A patent/EP3503923B1/en active Active
- 2017-08-23 SG SG11201901472TA patent/SG11201901472TA/en unknown
- 2017-08-23 BR BR112019003722A patent/BR112019003722A2/pt not_active Application Discontinuation
- 2017-08-23 CN CN201780062334.3A patent/CN109803684B/zh active Active
- 2017-08-23 IL IL264950A patent/IL264950B2/en unknown
- 2017-08-23 AU AU2017315357A patent/AU2017315357B2/en active Active
- 2017-08-23 MX MX2019002115A patent/MX2019002115A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528302A5 (OSRAM) | ||
| US20050209250A1 (en) | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | |
| US6432989B1 (en) | Use of CRF antagonists to treat circadian rhythm disorders | |
| RU2019108259A (ru) | Комбинированная терапия для лечения гепатоцеллюлярной карциномы | |
| CA2450777C (en) | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia | |
| CN101671336B (zh) | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 | |
| JP2020504136A5 (OSRAM) | ||
| US20100009934A1 (en) | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders | |
| TW201032806A (en) | Hsp90 inhibitor combinations | |
| KR101292508B1 (ko) | 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도 | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| AU6669500A (en) | Use of corticotropin releasing factor antagonists and related compositions | |
| AU2008276451A1 (en) | Treatments of B-cell proliferative disorders | |
| CN105294682A (zh) | Cdk类小分子抑制剂的化合物及其用途 | |
| RU2019132893A (ru) | Комбинированная терапия для лечения рака молочной железы | |
| US20210052528A1 (en) | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment | |
| JP2016537384A5 (OSRAM) | ||
| CN108430510B (zh) | 与中性肽链内切酶的抑制剂（NEP抑制剂）和/或血管紧张素AII拮抗剂组合的可溶性鸟苷酸环化酶（sGC）的刺激剂和/或活化剂及其用途 | |
| RU2013110124A (ru) | Комбинированная противораковая терапия | |
| ES2366116T3 (es) | Formulación farmacéutica que comprende melatonina. | |
| JP2005527583A5 (OSRAM) | ||
| JP2004501153A5 (OSRAM) | ||
| CN103554111A (zh) | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 | |
| WO2025179032A1 (en) | Methods of treating myelofibrosis | |
| JP2007517854A (ja) | Ｃｒｆアンタゴニスト及び５−ｈｔ１ｂ受容体アンタゴニストの組み合わせ |